Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product
This article was originally published in The Pink Sheet Daily
Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.
You may also be interested in...
Actelion is paying a $25 million upfront for an option to acquire Ceptaris Therapeutics, contingent upon the latter’s receiving FDA approval for its only asset, Valchlor, which faces an August PDUFA date. If the deal closes, Ceptaris will receive another $225 million plus milestones from the Swiss-based biotech.
Plus news on recent financings by bluebird bio, Puma Biotechnology, Atara Biotherapeutics and Aclaris Therapeutics.
Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.